LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Home・Aktien・Durect Corp

D
Durect Corp

Geschlossen

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

Max

Schlüsselkennzahlen
By Trading Economics
Angestellte	13

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+30.89% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	326K 51M
Vorheriger Eröffnungskurs	0
Vorheriger Schlusskurs	0

Durect Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Nov. 2025, 17:45 UTC

Ergebnisse

Wichtige Markttreiber

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14. Nov. 2025, 17:31 UTC

Ergebnisse

Wichtige Markttreiber

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

14. Nov. 2025, 16:15 UTC

Wichtige Markttreiber

Scholar Rock Shares Rise on Renewed Apitegromab Hopes

14. Nov. 2025, 23:56 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14. Nov. 2025, 23:02 UTC

Market Talk

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14. Nov. 2025, 22:35 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14. Nov. 2025, 22:32 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14. Nov. 2025, 22:29 UTC

Ergebnisse

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14. Nov. 2025, 22:00 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14. Nov. 2025, 21:50 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

14. Nov. 2025, 21:18 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14. Nov. 2025, 20:27 UTC

Market Talk

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14. Nov. 2025, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14. Nov. 2025, 20:17 UTC

Akquisitionen, Fusionen, Übernahmen

Several State Attorneys General Oppose Railroad Merger -- WSJ

14. Nov. 2025, 19:29 UTC

Market Talk

Ergebnisse

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14. Nov. 2025, 18:44 UTC

Market Talk

Ergebnisse

Disney's Growth Now Hinges More on ESPN -- Market Talk

14. Nov. 2025, 18:27 UTC

Market Talk

Global Equities Roundup: Market Talk

14. Nov. 2025, 18:27 UTC

Market Talk

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14. Nov. 2025, 18:20 UTC

Market Talk

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14. Nov. 2025, 17:20 UTC

Market Talk

Ergebnisse

Auto & Transport Roundup: Market Talk

14. Nov. 2025, 17:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Health Care Roundup: Market Talk

14. Nov. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14. Nov. 2025, 16:51 UTC

Market Talk

Starbucks Gets Holiday Sales Lift -- Market Talk

14. Nov. 2025, 16:48 UTC

Market Talk

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14. Nov. 2025, 16:38 UTC

Market Talk

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

14. Nov. 2025, 16:30 UTC

Akquisitionen, Fusionen, Übernahmen

Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com

14. Nov. 2025, 16:28 UTC

Market Talk

Ukraine Strike on Russian Port Lifts Distillates -- Market Talk

14. Nov. 2025, 15:59 UTC

Market Talk

U.S. Natural Gas Inventories Rise More Than Expected -- Market Talk

14. Nov. 2025, 15:06 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. Nov. 2025, 15:06 UTC

Market Talk

Dollar Could Benefit From U.K., French Fiscal Concerns -- Market Talk

Peer-Vergleich

Kursveränderung

Durect Corp Prognose

Kursziel

By TipRanks

30.89% Vorteil

12-Monats-Prognose

Durchschnitt 2.5 USD 30.89%

Hoch 2.5 USD

Tief 2.5 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Durect Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Durect Corp – Dist abgegeben haben.

Finanzen

Über Durect Corp

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.